Data update expands AML dataset from 5 to 30 patients
LEXINGTON, Mass., May 14, 2024 /PRNewswire/ — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3B1 Splicing Factor mutation (SFm) cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID.
|
|
Prior Data |
New
Data* |
|
Total |
|
|
| FLT3m AML | 3 | 9 |
|
12 |
|
|
| SFm AML | 3 | 17 |
|
20 |
|
|
| adjustment for patients with dual mutation** | (1) | (1) |
|
(2) |
|
|
|
|
5 | 25 |
|
30 |
|
|
|
|
|
|
|
|
|
|
* data cut-off as of February 26, 2024
** 2 patients had both FLT3m and SFm (dual mutation)
1 patient in the initial group of 5 patients; 1 patient in the new group of 25 additional patients
